Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | APAF1 | O14727 | 1/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | CASP6 | P55212 | 1/20 | 0.77 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.77 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.77 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.77 |
| ▸ | CTSV | O60911 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 3/20 | 0.60 |
| ▸ | CDC25B | P30305 | 3/20 | 0.56 |
| ▸ | FABP4 | P15090 | 3/20 | 0.54 |
| ▸ | FABP3 | P05413 | 2/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492334 | 0.90 | CTSV (0.65) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL9953735 | 0.89 | CTSV (0.69) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL29441241 | 0.87 | KDM4E (1.00) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL1720516 | 0.87 | KDM4E (1.00) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL19351590 | 0.81 | KDM4E (0.53) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL9953717 | 0.81 | KDM4E (0.85) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL22453646 | 0.81 | RECQL (0.61) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL19341855 | 0.81 | KDM4E (0.76) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL23286069 | 0.80 | KDM4E (0.83) | KDM4EAPAF1RECQLCASP6CACNA1B | |
| SCHEMBL9953689 | 0.80 | KDM4E (0.83) | KDM4EAPAF1RECQLCASP6CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2655334-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | Eutropics Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012088438-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088438-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL9 | KDM4E 1427/4885APAF1 111/4885RECQL 627/4885 |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL2L1 | KDM4E 709/4885APAF1 60/4885RECQL 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.